- Home
- BCAB vs CBUS Comparison
BCAB vs CBUS Comparison
Compare BCAB & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | CBUS |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 69.9M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BCAB | CBUS |
|---|---|---|
| Price | $0.31 | $1.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.0M | 260.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,794,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $109.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $1.09 |
| 52 Week High | $1.43 | $3.40 |
Technical Indicators
Market Signals| Indicator | BCAB | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 56.53 |
| Support Level | $0.40 | $1.86 |
| Resistance Level | $0.82 | $2.58 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 0.15 | 40.40 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.